Salivary Gland Carcinoma (SGC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Salivary gland malignancies are rare tumors that comprise multiple histologic entities with diverse clinical behavior. Mucoepidermoid carcinoma is the most frequent primary salivary malignancy that involves the parotid gland, followed by the submandibular and sublingual glands. The variation in histology and, in some cases, grade of malignancy may contribute to diversity in clinical behavior and prognosis of salivary gland malignancies. Although most salivary malignancies are asymptomatic, presentation with a rapidly enlarging mass may be accompanied by pain, functional neurologic deficits, soft-tissue invasion, or nodal enlargement. Primary salivary gland malignancies comprise a group of up to 20 distinct histopathologic entities present as an asymptomatic mass. However, some patients may experience rapid enlargement of the mass, soft tissue invasion, trismus, progressive loss of nerve function, pain, paresthesia, or development of enlarged neck nodes.
·
Salivary gland malignancies are rare entities
that contribute to approximately 5% of head and neck malignancies, and the
incidence of salivary gland carcinoma (SGC) has risen from 10.4 per one million
population.
Thelansis’s “Salivary Gland Carcinoma
(SGC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2022 To 2032" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Salivary Gland Carcinoma (SGC)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Salivary Gland Carcinoma (SGC) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Salivary Gland Carcinoma (SGC) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment